SUMMARIZED CONSOLIDATING INFORMATION - Consolidating Statement of Cash Flows (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	$ 372,475	$ 360,586	$ 135,789
Cash flows from investing activities:
Acquisition of real estate	(51,136)	(261,511)	(419,905)
Cash received in CCP Merger	0	0	77,859
Origination and fundings of loans receivable	(13,065)	(50,731)	(17,239)
Origination and fundings of preferred equity investments	0	(5,313)	(2,749)
Additions to real estate	(25,451)	(27,697)	(6,954)
Repayments of loans receivable	18,367	51,789	32,430
Repayments of preferred equity investments	5,079	6,870	3,755
Investment in unconsolidated joint venture	0	(354,461)	0
Net proceeds from sales of real estate	329,050	382,560	150,243
Distribution from subsidiaries	0	0	0
Intercompany financing	0	0	0
Net cash provided by (used in) investing activities	262,844	(258,494)	(182,560)
Cash flows from financing activities:
Net borrowings (repayments) from revolving credit facility	(624,000)	(17,000)	253,000
Proceeds from term loans	0	0	181,000
Proceeds from issuance of senior unsecured notes	638,779	0	0
Principal payments on senior unsecured notes	(700,000)	0	0
Principal payments on term loans	(145,000)	0	0
Principal payments on secured debt	(3,436)	(140,338)	(4,145)
Payments of deferred financing costs	(15,598)	(352)	(15,337)
Payments related to extinguishment of debt	(10,502)	(2,043)	0
Payment for Contingent Consideration Liability, Financing Activities	0	0	382
Distributions to noncontrolling interests	(316)	(142)	(30)
Issuance of common stock, net	549,328	(499)	366,800
Preferred stock redemption	0	(143,750)	0
Dividends paid on common and preferred stock	(335,435)	(325,220)	(182,089)
Distribution to parent	0	0	0
Intercompany financing	0	0	0
Net cash (used in) provided by financing activities	(646,180)	(629,344)	598,817
Net (decrease) increase in cash, cash equivalents and restricted cash	(10,861)	(527,252)	552,046
Effect of foreign currency translation on cash, cash equivalents and restricted cash	346	(539)	738
Cash, cash equivalents and restricted cash, beginning of period	59,658	587,449	34,665
Cash, cash equivalents and restricted cash, end of period	49,143	59,658	587,449
Elimination
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	0	0	0
Cash flows from investing activities:
Acquisition of real estate	0	0	0
Cash received in CCP Merger			0
Origination and fundings of loans receivable	0	0	0
Origination and fundings of preferred equity investments		0	0
Additions to real estate	0	0	0
Repayments of loans receivable	0	0	0
Repayments of preferred equity investments	0	0	0
Investment in unconsolidated joint venture		0
Net proceeds from sales of real estate	0	0	0
Distribution from subsidiaries	(10,496)	(10,914)	(4,948)
Intercompany financing	324,025	619,141	80,665
Net cash provided by (used in) investing activities	313,529	608,227	75,717
Cash flows from financing activities:
Net borrowings (repayments) from revolving credit facility	0	0	0
Proceeds from term loans			0
Proceeds from issuance of senior unsecured notes	0
Principal payments on senior unsecured notes	0
Principal payments on term loans	0
Principal payments on secured debt	0	0	0
Payments of deferred financing costs	0	0	0
Payments related to extinguishment of debt	0	0
Payment for Contingent Consideration Liability, Financing Activities			0
Distributions to noncontrolling interests	0	0	0
Issuance of common stock, net	0	0	0
Preferred stock redemption		0
Dividends paid on common and preferred stock	0	0	0
Distribution to parent	10,496	10,914	4,948
Intercompany financing	(324,025)	(619,141)	(80,665)
Net cash (used in) provided by financing activities	(313,529)	(608,227)	(75,717)
Net (decrease) increase in cash, cash equivalents and restricted cash	0	0	0
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0	0
Cash, cash equivalents and restricted cash, end of period	0	0	0
Parent Company | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	359,681	312,485	59,640
Cash flows from investing activities:
Acquisition of real estate	0	0	0
Cash received in CCP Merger			77,859
Origination and fundings of loans receivable	0	0	0
Origination and fundings of preferred equity investments		0	0
Additions to real estate	(115)	(40)	(181)
Repayments of loans receivable	0	0	0
Repayments of preferred equity investments	0	0	0
Investment in unconsolidated joint venture		0
Net proceeds from sales of real estate	0	0	0
Distribution from subsidiaries	5,248	5,457	2,474
Intercompany financing	(590,173)	(319,268)	168,999
Net cash provided by (used in) investing activities	(585,040)	(313,851)	249,151
Cash flows from financing activities:
Net borrowings (repayments) from revolving credit facility	0	0	0
Proceeds from term loans			0
Proceeds from issuance of senior unsecured notes	0
Principal payments on senior unsecured notes	0
Principal payments on term loans	0
Principal payments on secured debt	0	0	0
Payments of deferred financing costs	0	0	0
Payments related to extinguishment of debt	0	0
Payment for Contingent Consideration Liability, Financing Activities			0
Distributions to noncontrolling interests	0	0	0
Issuance of common stock, net	549,328	(499)	366,800
Preferred stock redemption		(143,750)
Dividends paid on common and preferred stock	(335,435)	(325,220)	(182,089)
Distribution to parent	0	0	0
Intercompany financing	0	0	0
Net cash (used in) provided by financing activities	213,893	(469,469)	184,711
Net (decrease) increase in cash, cash equivalents and restricted cash	(11,466)	(470,835)	493,502
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0	0
Cash, cash equivalents and restricted cash, beginning of period	40,835	511,670	18,168
Cash, cash equivalents and restricted cash, end of period	29,369	40,835	511,670
Operating Partnership | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	0	0	0
Cash flows from investing activities:
Acquisition of real estate	0	0	0
Cash received in CCP Merger			0
Origination and fundings of loans receivable	0	0	0
Origination and fundings of preferred equity investments		0	0
Additions to real estate	0	0	0
Repayments of loans receivable	0	0	0
Repayments of preferred equity investments	0	0	0
Investment in unconsolidated joint venture		0
Net proceeds from sales of real estate	0	0	0
Distribution from subsidiaries	5,248	5,457	2,474
Intercompany financing	266,148	(299,873)	(249,664)
Net cash provided by (used in) investing activities	271,396	(294,416)	(247,190)
Cash flows from financing activities:
Net borrowings (repayments) from revolving credit facility	(624,000)	(17,000)	253,000
Proceeds from term loans			181,000
Proceeds from issuance of senior unsecured notes	638,779
Principal payments on senior unsecured notes	(700,000)
Principal payments on term loans	(145,000)
Principal payments on secured debt	0	0	0
Payments of deferred financing costs	(15,598)	(352)	(15,337)
Payments related to extinguishment of debt	(10,502)	(2,043)
Payment for Contingent Consideration Liability, Financing Activities			0
Distributions to noncontrolling interests	0	0	0
Issuance of common stock, net	0	0	0
Preferred stock redemption		0
Dividends paid on common and preferred stock	0	0	0
Distribution to parent	(5,248)	(5,457)	(2,474)
Intercompany financing	590,173	319,268	(168,999)
Net cash (used in) provided by financing activities	(271,396)	294,416	247,190
Net (decrease) increase in cash, cash equivalents and restricted cash	0	0	0
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0	0
Cash, cash equivalents and restricted cash, end of period	0	0	0
Sabra Health Care, L.L.C. | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	0	0	0
Cash flows from investing activities:
Acquisition of real estate	0	0	0
Cash received in CCP Merger			0
Origination and fundings of loans receivable	0	0	0
Origination and fundings of preferred equity investments		0	0
Additions to real estate	0	0	0
Repayments of loans receivable	0	0	0
Repayments of preferred equity investments	0	0	0
Investment in unconsolidated joint venture		0
Net proceeds from sales of real estate	0	0	0
Distribution from subsidiaries	0	0	0
Intercompany financing	0	0	0
Net cash provided by (used in) investing activities	0	0	0
Cash flows from financing activities:
Net borrowings (repayments) from revolving credit facility	0	0	0
Proceeds from term loans			0
Proceeds from issuance of senior unsecured notes	0
Principal payments on senior unsecured notes	0
Principal payments on term loans	0
Principal payments on secured debt	0	0	0
Payments of deferred financing costs	0	0	0
Payments related to extinguishment of debt	0	0
Payment for Contingent Consideration Liability, Financing Activities			0
Distributions to noncontrolling interests	0	0	0
Issuance of common stock, net	0	0	0
Preferred stock redemption		0
Dividends paid on common and preferred stock	0	0	0
Distribution to parent	0	0	0
Intercompany financing	0	0	0
Net cash (used in) provided by financing activities	0	0	0
Net (decrease) increase in cash, cash equivalents and restricted cash	0	0	0
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0	0
Cash, cash equivalents and restricted cash, end of period	0	0	0
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by operating activities	12,794	48,101	76,149
Cash flows from investing activities:
Acquisition of real estate	(51,136)	(261,511)	(419,905)
Cash received in CCP Merger			0
Origination and fundings of loans receivable	(13,065)	(50,731)	(17,239)
Origination and fundings of preferred equity investments		(5,313)	(2,749)
Additions to real estate	(25,336)	(27,657)	(6,773)
Repayments of loans receivable	18,367	51,789	32,430
Repayments of preferred equity investments	5,079	6,870	3,755
Investment in unconsolidated joint venture		(354,461)
Net proceeds from sales of real estate	329,050	382,560	150,243
Distribution from subsidiaries	0	0	0
Intercompany financing	0	0	0
Net cash provided by (used in) investing activities	262,959	(258,454)	(260,238)
Cash flows from financing activities:
Net borrowings (repayments) from revolving credit facility	0	0	0
Proceeds from term loans			0
Proceeds from issuance of senior unsecured notes	0
Principal payments on senior unsecured notes	0
Principal payments on term loans	0
Principal payments on secured debt	(3,436)	(140,338)	(4,145)
Payments of deferred financing costs	0	0	0
Payments related to extinguishment of debt	0	0
Payment for Contingent Consideration Liability, Financing Activities			382
Distributions to noncontrolling interests	(316)	(142)	(30)
Issuance of common stock, net	0	0	0
Preferred stock redemption		0
Dividends paid on common and preferred stock	0	0	0
Distribution to parent	(5,248)	(5,457)	(2,474)
Intercompany financing	(266,148)	299,873	249,664
Net cash (used in) provided by financing activities	(275,148)	153,936	242,633
Net (decrease) increase in cash, cash equivalents and restricted cash	605	(56,417)	58,544
Effect of foreign currency translation on cash, cash equivalents and restricted cash	346	(539)	738
Cash, cash equivalents and restricted cash, beginning of period	18,823	75,779	16,497
Cash, cash equivalents and restricted cash, end of period	$ 19,774	$ 18,823	$ 75,779